ViengKham Pharmaceutical Co., Ltd. Announces AI-Driven Healthy Longevity Initiative
ViengKham Pharmaceutical Co., Ltd. believes that artificial intelligence is becoming an important infrastructure in the field of life sciences. In recent years, AI has been widely applied in drug discovery, protein design, disease mechanism research, biological age assessment, and multi-omics data analysis. AI technologies can help researchers identify potential targets more quickly, screen candidate compounds, predict molecular and protein interactions, and improve early-stage R&D efficiency. In 2026, Chan Zuckerberg Biohub launched an AI world model for protein biology, further demonstrating the potential of AI in drug discovery and protein engineering.
ViengKham Pharmaceutical Co., Ltd. Announces AI-Driven Healthy Longevity Initiative
Vientiane, Laos, May 29, 2026 — ViengKham Pharmaceutical Co., Ltd. today announced that the company will integrate artificial intelligence, life sciences, and modern pharmaceutical technologies to formally launch its “AI Healthy Longevity” initiative. Through a new-generation digital R&D platform, intelligent drug discovery, biomarker analysis, and precision health management technologies, the company aims to explore new pathways to extend human healthspan.
As the global population continues to age, healthy longevity has become an important topic in public health and the pharmaceutical industry. According to the World Health Organization, by 2030, one in six people worldwide will be aged 60 years or older; by 2050, the global population aged 60 and above is expected to reach 2.1 billion. At the same time, there remains a gap between life expectancy and healthy life expectancy, which means that more people are not only seeking to “live longer,” but also to “live healthier for longer.”
ViengKham Pharmaceutical Co., Ltd. believes that artificial intelligence is becoming an important infrastructure in the field of life sciences. In recent years, AI has been widely applied in drug discovery, protein design, disease mechanism research, biological age assessment, and multi-omics data analysis. AI technologies can help researchers identify potential targets more quickly, screen candidate compounds, predict molecular and protein interactions, and improve early-stage R&D efficiency. In 2026, Chan Zuckerberg Biohub launched an AI world model for protein biology, further demonstrating the potential of AI in drug discovery and protein engineering.
The company plans to build long-term R&D capabilities in the following areas:
First, building an AI-driven healthy longevity R&D platform.
The platform will integrate public scientific research data, medicinal chemistry data, biomarker data, and preclinical research information to support target discovery, formulation optimization, candidate product screening, and R&D decision-making.
Second, exploring products related to healthy aging.
The company will focus on research areas closely associated with healthspan, including metabolic health, chronic inflammation, cellular senescence, mitochondrial function, oxidative stress, immune regulation, and neuroprotection.
Third, integrating traditional pharmaceutical manufacturing with AI technologies.
ViengKham Pharmaceutical Co., Ltd. will introduce AI tools into drug research and development, quality control, production process optimization, stability studies, and digital GMP management to improve R&D efficiency, product consistency, and quality management standards.
Fourth, establishing a regional healthy longevity research cooperation network.
The company will actively seek collaboration with universities, research institutions, medical institutions, and international technology platforms to jointly promote the development of healthy aging and precision health industries in Southeast Asia.
ViengKham Pharmaceutical Co., Ltd. stated: “The future of life sciences is not only about treating diseases, but also about helping people extend their health, vitality, and quality of life. AI gives us the opportunity to understand the aging process in a faster, more precise, and more systematic way. Our goal is not to exaggerate the idea of ‘immortality,’ but to provide practical and verifiable solutions for extending healthspan through rigorous science and compliant R&D.”
In recent years, longevity biotechnology has been moving from concept to industrial application. Researchers are increasingly focusing on the integration of AI, aging biomarkers, geriatric medicine, regenerative medicine, and drug discovery. Relevant reviews indicate that key applications of AI in aging research include drug discovery, biological age assessment, multi-omics analysis, and the screening of potential anti-aging interventions.
ViengKham Pharmaceutical Co., Ltd. emphasizes that all future product development and communication will adhere to scientific, compliant, and safety-based principles, and will strictly follow relevant regulatory requirements for medicines, health products, food products, and medical health products. The company will not present unverified technologies as medical promises, nor will it mislead the public with claims such as “reversing aging” or “guaranteed life extension.”
Looking ahead, ViengKham Pharmaceutical Co., Ltd. will be based in Laos and serve Southeast Asian and international markets. The company will continue to promote AI-driven pharmaceutical development, healthy longevity technologies, and modern GMP manufacturing systems, striving to become a life sciences enterprise with innovation capabilities and social responsibility in the region.
About ViengKham Pharmaceutical Co., Ltd.
ViengKham Pharmaceutical Co., Ltd. is an enterprise focused on modern pharmaceuticals, health product R&D, and pharmaceutical industry upgrading. The company is committed to advancing the healthcare industry through scientific research, quality management, and international standards, providing safe, reliable, and affordable health solutions to more people.
Media Contact
ViengKham Pharmaceutical Co., Ltd.
Email: laoviengkham@gmail.com
Vientiane, Laos, May 29, 2026 — ViengKham Pharmaceutical Co., Ltd. today announced that the company will integrate artificial intelligence, life sciences, and modern pharmaceutical technologies to formally launch its “AI Healthy Longevity” initiative. Through a new-generation digital R&D platform, intelligent drug discovery, biomarker analysis, and precision health management technologies, the company aims to explore new pathways to extend human healthspan.
As the global population continues to age, healthy longevity has become an important topic in public health and the pharmaceutical industry. According to the World Health Organization, by 2030, one in six people worldwide will be aged 60 years or older; by 2050, the global population aged 60 and above is expected to reach 2.1 billion. At the same time, there remains a gap between life expectancy and healthy life expectancy, which means that more people are not only seeking to “live longer,” but also to “live healthier for longer.”
ViengKham Pharmaceutical Co., Ltd. believes that artificial intelligence is becoming an important infrastructure in the field of life sciences. In recent years, AI has been widely applied in drug discovery, protein design, disease mechanism research, biological age assessment, and multi-omics data analysis. AI technologies can help researchers identify potential targets more quickly, screen candidate compounds, predict molecular and protein interactions, and improve early-stage R&D efficiency. In 2026, Chan Zuckerberg Biohub launched an AI world model for protein biology, further demonstrating the potential of AI in drug discovery and protein engineering.
The company plans to build long-term R&D capabilities in the following areas:
First, building an AI-driven healthy longevity R&D platform.
The platform will integrate public scientific research data, medicinal chemistry data, biomarker data, and preclinical research information to support target discovery, formulation optimization, candidate product screening, and R&D decision-making.
Second, exploring products related to healthy aging.
The company will focus on research areas closely associated with healthspan, including metabolic health, chronic inflammation, cellular senescence, mitochondrial function, oxidative stress, immune regulation, and neuroprotection.
Third, integrating traditional pharmaceutical manufacturing with AI technologies.
ViengKham Pharmaceutical Co., Ltd. will introduce AI tools into drug research and development, quality control, production process optimization, stability studies, and digital GMP management to improve R&D efficiency, product consistency, and quality management standards.
Fourth, establishing a regional healthy longevity research cooperation network.
The company will actively seek collaboration with universities, research institutions, medical institutions, and international technology platforms to jointly promote the development of healthy aging and precision health industries in Southeast Asia.
ViengKham Pharmaceutical Co., Ltd. stated: “The future of life sciences is not only about treating diseases, but also about helping people extend their health, vitality, and quality of life. AI gives us the opportunity to understand the aging process in a faster, more precise, and more systematic way. Our goal is not to exaggerate the idea of ‘immortality,’ but to provide practical and verifiable solutions for extending healthspan through rigorous science and compliant R&D.”
In recent years, longevity biotechnology has been moving from concept to industrial application. Researchers are increasingly focusing on the integration of AI, aging biomarkers, geriatric medicine, regenerative medicine, and drug discovery. Relevant reviews indicate that key applications of AI in aging research include drug discovery, biological age assessment, multi-omics analysis, and the screening of potential anti-aging interventions.
ViengKham Pharmaceutical Co., Ltd. emphasizes that all future product development and communication will adhere to scientific, compliant, and safety-based principles, and will strictly follow relevant regulatory requirements for medicines, health products, food products, and medical health products. The company will not present unverified technologies as medical promises, nor will it mislead the public with claims such as “reversing aging” or “guaranteed life extension.”
Looking ahead, ViengKham Pharmaceutical Co., Ltd. will be based in Laos and serve Southeast Asian and international markets. The company will continue to promote AI-driven pharmaceutical development, healthy longevity technologies, and modern GMP manufacturing systems, striving to become a life sciences enterprise with innovation capabilities and social responsibility in the region.
About ViengKham Pharmaceutical Co., Ltd.
ViengKham Pharmaceutical Co., Ltd. is an enterprise focused on modern pharmaceuticals, health product R&D, and pharmaceutical industry upgrading. The company is committed to advancing the healthcare industry through scientific research, quality management, and international standards, providing safe, reliable, and affordable health solutions to more people.
Media Contact
ViengKham Pharmaceutical Co., Ltd.
Email: laoviengkham@gmail.com